David Angulo

1.7k citations

33 papers · 1.2k indexed · 1 hit paper · h-index 18

Impact in

Infectious Diseases top 1%
- Antifungal resistance and susceptibility
- Antimicrobial Resistance in Staphylococcus
Epidemiology top 5%
- Fungal Infections and Studies
- Nail Diseases and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment

Papers in ⓘ

Infectious Diseases 29
- Antifungal resistance and susceptibility 29
Epidemiology 25
- Fungal Infections and Studies 16
- Nail Diseases and Treatments 12
- Pneumocystis jirovecii pneumonia detection and treatment 3

Co-authors: Katyna Borroto–Esoda (14 shared papers)Nkechi Azie (15 shared papers)Stephen A. Wring (5 shared papers)Mahmoud A. Ghannoum (6 shared papers)Pranab K. Mukherjee (1 shared paper)Iman Salem (1 shared paper)Laura Kovanda (1 shared paper)Emily L. Larkin (1 shared paper)
Journals: Antimicrobial Agents and Chemotherapy (9 papers)Open Forum Infectious Diseases (7 papers)Clinical Infectious Diseases (2 papers)Medical Mycology (2 papers)Obstetrics and Gynecology (2 papers)
Partner nations: United States Austria United Kingdom

In The Last Decade

David Angulo

33 papers receiving 1.2k citations

Hit Papers

align trajectories log scale

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation 2017 · 316 citations

Peers

Countries citing papers authored by David Angulo

Since Specialization

Citations

This map shows the geographic impact of David Angulo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Angulo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Angulo more than expected).

Fields of papers citing papers by David Angulo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Angulo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Angulo. The network helps show where David Angulo may publish in the future.

Co-authors

The 25 scholars most cited alongside David Angulo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Angulo Line = papers co-authored together David Angulo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation Antimicrobial Agents and Chemotherapy ·Emily L. Larkin, Christopher Hager, Jyotsna Chandra, Pranab K. Mukherjee, Mauricio Retuerto, Iman Salem, Lisa Long, N. Isham, Laura Kovanda, Katyna Borroto–Esoda, Steve Wring, David Angulo, Mahmoud Ghannoum Hit paper breakdown →	2017	316
2	Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Gopal Krishna, Malaz Abutarif, Fengjuan Xuan, Monika Martinho, David Angulo, Oliver A. Cornely	2008	82
3	Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis Antimicrobial Agents and Chemotherapy ·Stephen A. Wring, Ryan Randolph, Seonghee Park, George K. Abruzzo, Qing Chen, Amy Flattery, Graig Garrett, Michael Peel, Russell J. Outcalt, Kendall D. Powell, Michelle Trucksis, David Angulo, Katyna Borroto–Esoda	2017	75
4	Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections Antibiotics ·Mahmoud A. Ghannoum, Maiken Cavling Arendrup, Vishnu Chaturvedi, Shawn R. Lockhart, Thomas S. McCormick, Sudha Chaturvedi, Elizabeth L. Berkow, Deven Juneja, Bansidhar Tarai, Nkechi Azie, David Angulo, Thomas J. Walsh	2020	71
5	De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance Antimicrobial Agents and Chemotherapy ·Cristina Jiménez‐Ortigosa, Winder B. Perez, David Angulo, Katyna Borroto–Esoda, David S. Perlin	2017	68
6	SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies Antimicrobial Agents and Chemotherapy ·Bernard Scorneaux, David Angulo, Katyna Borroto–Esoda, Mahmoud A. Ghannoum, Michael Peel, Stephen A. Wring	2017	67
7	Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303) Clinical Infectious Diseases ·Jane R. Schwebke, Ryan Sobel, Janet Gersten, Steven A. Sussman, Samuel Lederman, Mark Jacobs, B. Todd Chappell, David Weinstein, Alfred H. Moffett, Nkechi Azie, David Angulo, Itzel A Harriott, Katyna Borroto–Esoda, Mahmoud A. Ghannoum, Paul Nyirjesy, Jack D. Sobel	2021	62
8	In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations Antimicrobial Agents and Chemotherapy ·Natalie S. Nunnally, Kizee A. Etienne, David Angulo, Shawn R. Lockhart, Elizabeth L. Berkow	2019	47
9	Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata Frontiers in Cellular and Infection Microbiology ·Ahmed Gamal, Sherman Chu, Thomas S. McCormick, Katyna Borroto–Esoda, David Angulo, Mahmoud A. Ghannoum	2021	40
10	Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis Expert Opinion on Investigational Drugs ·Nkechi Azie, David Angulo, Barbara Dehn, Jack D. Sobel	2020	40
11	Clinical Pharmacokinetics and Drug‐Drug Interaction Potential for Coadministered SCY‐078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus Clinical Pharmacology in Drug Development ·Stephen A. Wring, Gail Murphy, George Atiee, Christy Corr, Michele Hyman, Michael S. Willett, David Angulo	2018	39
12	SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [ ¹⁴ C]SCY-078 in Albino and Pigmented Rats Antimicrobial Agents and Chemotherapy ·Stephen A. Wring, Katyna Borroto–Esoda, Eric Solon, David Angulo	2018	36
13	Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections Journal of Fungi ·David Angulo, Barbara D. Alexander, Riina Rautemaa‐Richardson, Ana Alastruey‐Izquierdo, Martin Hoenigl, Ashraf S. Ibrahim, Mahmoud A. Ghannoum, Thomas King, Nkechi Azie, Thomas J. Walsh	2022	34
14	Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions The Journal of Clinical Pharmacology ·Stephen A. Wring, Gail Murphy, George Atiee, Christy Corr, Michele Hyman, Michael S. Willett, David Angulo	2018	33
15	Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis Antimicrobial Agents and Chemotherapy ·Vidmantas Petraitis, Rūta Petraitienė, Aspasia Katragkou, Bo Bo Win Maung, Ethan Naing, Povilas Kavaliauskas, Stephen Barat, Katyna Borroto–Esoda, Nkechi Azie, David Angulo, Thomas J. Walsh	2020	32
16	Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis Clinical Infectious Diseases ·Paul Nyirjesy, Jane R. Schwebke, David Angulo, Itzel A Harriott, Nkechi Azie, Jack D. Sobel	2021	27
17	Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model Antimicrobial Agents and Chemotherapy ·Annie Lee, Brendan Prideaux, Matthew Zimmerman, Claire Carter, Stephen Barat, David Angulo, Véronique Dartois, David S. Perlin, Yanan Zhao	2019	21
18	Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306 Journal of Women s Health ·Oluwatosin Goje, Ryan Sobel, Paul Nyirjesy, Steven R. Goldstein, Mark Spitzer, Brooke Faught, Shelagh Larson, Thomas King, Nkechi Azie, David Angulo, Jack D. Sobel	2022	18
19	In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis Antimicrobial Agents and Chemotherapy ·Jack D. Sobel, Katyna Borroto–Esoda, Nkechi Azie, David Angulo	2021	17
20	871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI) Open Forum Infectious Diseases ·George R. Thompson, Thomas King, Nkechi Azie, David Angulo, Juergen Prattes	2022	13

About David Angulo

David Angulo is a scholar working on Infectious Diseases, Epidemiology, Pharmacology, Microbiology and Oncology, having authored 33 papers that have together received 1.2k indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (29 papers), Fungal Infections and Studies (16 papers), Nail Diseases and Treatments (12 papers), Fungal Biology and Applications (7 papers), Reproductive tract infections research (5 papers), Peptidase Inhibition and Analysis (3 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers) and Plant Pathogens and Fungal Diseases (2 papers). The work is most often cited by research in Infectious Diseases (1.0k citations), Epidemiology (888 citations), Microbiology (122 citations), Applied Microbiology and Biotechnology (18 citations) and Pharmacology (143 citations). David Angulo has collaborated with scholars based in United States, Austria and United Kingdom. Frequent co-authors include Katyna Borroto–Esoda, Nkechi Azie, Stephen A. Wring, Mahmoud A. Ghannoum, Pranab K. Mukherjee, Iman Salem, Laura Kovanda, Emily L. Larkin, Lisa Long and Jyotsna Chandra. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Open Forum Infectious Diseases, Clinical Infectious Diseases, Medical Mycology and Obstetrics and Gynecology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact